Hormonal
Semaglutide 2.4 mg improves anthropometric measures (waist circumference, waist-to-height ratio, BMI category) and reduces serious adverse events in patients with obesity and cardiovascular disease, regardless of baseline BMI category.
Semaglutide 2.4 mg not only reduces overall weight but also specifically targets visceral fat (waist circumference) and improves waist-to-height ratio, which are key markers for cardiovascular risk. These benefits, along with a reduced rate of serious adverse events, are consistent across all obesity classes, including those with a BMI just over 30.
Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category... there were lower rates... of serious adverse events with semaglutide
Why this rating
Large-scale RCT with subgroup analyses confirming consistency across BMI categories.
Source
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Donna H. Ryan et al. · Nature Medicine · 2024
DOI 10.1038/s41591-024-02996-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →